Neurocrine Biosciences (NBIX) Common Equity (2010 - 2026)

Neurocrine Biosciences has reported Common Equity for 17 years, with the latest figure at $3.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 34.38% year-over-year to $3.4 billion; the trailing twelve-month figure through Mar 2026 stood at $3.4 billion (up 34.38% YoY), and the FY2025 full-year result was $3.3 billion, up 25.62% from the prior year.
• Common Equity for Q1 2026 stood at $3.4 billion, up from $3.3 billion in the prior quarter.
• The five-year high for Common Equity was $3.4 billion in Q1 2026, with the low at $1.4 billion in Q1 2022.
• Historically, Common Equity has averaged $2.3 billion across 5 years, with a median of $2.4 billion in 2024.
• Annual changes were most pronounced in 2024 — Common Equity surged 41.65% — and 2025, when it grew 6.27%.
• Neurocrine Biosciences' Common Equity stood at $1.7 billion in 2022, then jumped by 30.69% to $2.2 billion in 2023, then increased by 16.03% to $2.6 billion in 2024, then grew by 25.62% to $3.3 billion in 2025, then increased by 4.74% to $3.4 billion in 2026.
• The last three Common Equity figures came in at $3.4 billion (Q1 2026), $3.3 billion (Q4 2025), and $3.0 billion (Q3 2025), per Business Quant data.